Aspen drops lenacapavir HIV prevention injection for unproven alimatravir pill

Aspen Pharmacare announced it will not manufacture the lenacapavir HIV prevention injection, pivoting instead to alimatravir, an experimental oral HIV prevention pill. The decision is a strategic shift away from a proven long-acting injectable toward an unproven candidate, raising questions about access to effective prevention in high-burden regions. The move may reflect manufacturing or licensing considerations, but the rationale is not fully disclosed.